Evidence map›Paper›PMID 38334384›Full record

ArticleMicrobiology spectrum2024

Refined understanding of the impact of the

Praharshinie Rupasinghe, Rabab Reenaers, Jens Vereecken, Wim Mulders, Sari Cogneau, Matthias Merker, Stefan Niemann, Shaheed Vally Omar, Leen Rigouts, Claudio U Köser and 2 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Antimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Antimicrobial agents and chemotherapy · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Praharshinie RupasingheUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-9858-8935
Rabab ReenaersUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Jens VereeckenUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Wim MuldersUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Sari CogneauUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Matthias MerkerMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Stefan NiemannMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Shaheed Vally OmarCenter for Tuberculosis, National Institute of Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.
Leen RigoutsUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0003-3301-9480
Claudio U KöserDepartment of Genetics, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-0232-846X
Tom DecrooUnit of HIV and TB, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Bouke C de JongUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Instituut voor Tropische Geneeskunde · BEGerman Center for Infection Research · DEUniversity of Antwerp · BENational Health Laboratory Service · ZAUniversity of Cambridge · GB

Funding

Flandre | Departement Economie, Wetenschap en Innovatie (EWI)
6 · The paper itself

Abstract

Previous work reported unprecedented differences in the intrinsic IMPORTANCE: This study confirmed that the

Indexed as

Anti-Infective AgentsMycobacterium tuberculosisNitroimidazolesTuberculosisAntitubercular AgentsHumansMicrobial Sensitivity TestsAnti-Infective AgentsAntitubercular AgentsNitroimidazolespretomanidMTBC lineagesMycobacterium tuberculosispretomanid

Identifiers

PMID38334384
PMCPMC10913522
OpenAlexW4391679728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.